Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Earns “Buy” Rating from D. Boral Capital

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)‘s stock had its “buy” rating reaffirmed by equities researchers at D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They currently have a $2.00 price objective on the stock. D. Boral Capital’s target price suggests a potential upside of 102.04% from the stock’s current price.

Separately, HC Wainwright restated a “buy” rating and issued a $9.00 target price on shares of Lineage Cell Therapeutics in a research note on Monday, June 23rd. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Lineage Cell Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $4.20.

Lineage Cell Therapeutics Price Performance

NYSEAMERICAN:LCTX opened at $0.99 on Tuesday. Lineage Cell Therapeutics has a fifty-two week low of $0.37 and a fifty-two week high of $1.21. The stock has a market capitalization of $226.05 million, a PE ratio of -12.37 and a beta of 1.66. The business’s 50-day simple moving average is $0.93 and its 200-day simple moving average is $0.66.

Institutional Trading of Lineage Cell Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Broadwood Capital Inc. raised its position in Lineage Cell Therapeutics by 18.9% in the first quarter. Broadwood Capital Inc. now owns 49,560,992 shares of the company’s stock valued at $22,382,000 after purchasing an additional 7,894,737 shares during the last quarter. Alyeska Investment Group L.P. bought a new position in Lineage Cell Therapeutics in the fourth quarter valued at about $1,984,000. Comerica Bank raised its position in Lineage Cell Therapeutics by 275.0% in the first quarter. Comerica Bank now owns 3,000,000 shares of the company’s stock valued at $1,355,000 after purchasing an additional 2,200,000 shares during the last quarter. Renaissance Technologies LLC raised its position in Lineage Cell Therapeutics by 1,058.3% in the fourth quarter. Renaissance Technologies LLC now owns 2,283,072 shares of the company’s stock valued at $1,147,000 after purchasing an additional 2,085,972 shares during the last quarter. Finally, DAFNA Capital Management LLC raised its position in Lineage Cell Therapeutics by 85.9% in the fourth quarter. DAFNA Capital Management LLC now owns 2,511,374 shares of the company’s stock valued at $1,262,000 after purchasing an additional 1,160,666 shares during the last quarter. 62.47% of the stock is currently owned by institutional investors.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.